Asymmetrex Will Present at ISSCR 2021 Annual Meeting a New Test for Therapeutic Stem Cell Potency

Jun 17, 2021

Asymmetrex introduces new test for stem cell treatment potency

Posted by

Next week from June 21-26, stem cell biotechnology company Asymmetrex will participate as a presenter and an exhibitor in the 2021 Annual Meeting of the International Society of Stem Cell Research.  In an invited poster presentation (#345) and a company exhibitor display, Asymmetrex will introduce the virtual gathering of international stem cell scientists, physicians, and biotechnologists to its new technology for evaluating the potency of therapeutic tissue stem cells.


Potency tests assure doctors that a medicine has good quality and will be effective for treatment.  Although potency tests are common for drug medicines, developing them for stem cell treatments has been difficult.  For stem cell treatments, no reliable potency tests have been available.


At the June 21-26, 2021 Annual Meeting of the International Society of Stem Cell Research, stem cell biotechnology company Asymmetrex will present data and examples of a new test for evaluation of the potency of tissue stem cell treatments.  The technology, called kinetic stem cell (KSC) counting, can tell doctors the number of live tissue-renewing stem cells in a treatment sample.


The President & CEO of Asymmetrex, James L. Sherley, M.D., Ph.D., explains, “Stem cell medicine has needed a quality and effectiveness index like drug specific activity for pharmaceuticals.  What could work better than knowing the number of live tissue stem cells that can restore other tissue cells?  That’s what our KSC counting TORTOISE TestTM platform can tell doctors: the number of live stem cells in a treatment that can renew an organ or tissue.”


Asymmetrex is currently focused on conducting preclinical and clinical evaluations of how well its tissue stem cell-specific data indicates the effectiveness of stem cell treatments in different patients.  In his company’s presentations at ISSCR 2021, Sherley says that he will also introduce the immediate benefits of KSC counting to stem cell scientists for their tissue stem cell research.  “It’s a no brainer that now knowing how many tissue stem cells are in experiments will greatly improve stem cell research…and, as a consequence, stem cell medicine.”



About Asymmetrex


Asymmetrex, LLC is a Massachusetts life sciences company with a focus on developing technologies to advance stem cell medicine.  Asymmetrex is a member company of the Advanced Regenerative Manufacturing Institute BioFabUSA (ARMI) and the Massachusetts Biotechnology Council.

Download Attachment

See all Member News